MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: MT-5625 middle dose
Biological: MT-5625 low dose
Biological: MT-5625 high dose
Biological: Rotarix
Biological: Placebo

First Posted Date: 2018-04-25

Last Posted Date: 2019-08-06

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 110

Registration Number: NCT03507738

Locations: 🇿🇦
Investigational center, Johannesburg, South Africa

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Phase 3

Completed

Conditions: Anemia; Hemodialysis Dependent Chronic Kidney Disease

Interventions: Drug: MT-6548

First Posted Date: 2018-03-09

Last Posted Date: 2023-12-29

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 24

Registration Number: NCT03461146

Locations: 🇯🇵
Research site, Yamagata, Japan

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Phase 3

Completed

Conditions: Anemia; Hemodialysis Dependent Chronic Kidney Disease

Interventions: Drug: MT-6548
Drug: Darbepoetin alfa
Drug: Darbepoetin alfa-matching placebo
Drug: MT-6548-matching placebo

First Posted Date: 2018-02-20

Last Posted Date: 2023-12-28

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 323

Registration Number: NCT03439137

Locations: 🇯🇵
Research site, Yamagata, Japan

Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Phase 3

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: Canagliflozin
Drug: Placebo

First Posted Date: 2018-02-19

Last Posted Date: 2024-07-15

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 308

Registration Number: NCT03436693

Locations: 🇯🇵
Research site, Yamaguchi, Japan

Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Phase 3

Completed

Conditions: Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease

Interventions: Drug: MT-6548

First Posted Date: 2018-01-18

Last Posted Date: 2023-12-28

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 42

Registration Number: NCT03402386

Locations: 🇯🇵
Research site, Tokyo, Japan

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

Phase 2

Terminated

Conditions: Acute Ischemic Stroke

Interventions: Drug: Continuous infusion low-dose MCI-186
Drug: Continuous infusion high-dose MCI-186
Drug: Continuous infusion placebo
Drug: Approved dosing regimen MCI-186
Drug: Approved dosing regimen placebo

First Posted Date: 2017-11-17

Last Posted Date: 2025-01-09

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 17

Registration Number: NCT03346538

Locations: 🇯🇵
Investigational site 03, Osaka, Japan
🇯🇵
Investigational site 12, Fukuoka, Japan
🇯🇵
Investigational site 20, Nagano, Japan

and more 42 locations

Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Phase 3

Completed

Conditions: Anemia; Non-dialysis Dependent Chronic Kidney Disease

Interventions: Drug: MT-6548
Drug: Darbepoetin alfa

First Posted Date: 2017-11-01

Last Posted Date: 2023-12-28

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 304

Registration Number: NCT03329196

Locations: 🇯🇵
Research site, Yamanashi, Japan

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy

Interventions: Drug: MCI-186

First Posted Date: 2017-09-20

Last Posted Date: 2023-04-05

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 22

Registration Number: NCT03289234

Locations: 🇯🇵
Investigational site, Tokyo, Japan

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment
Healthy

Interventions: Drug: MCI-186

First Posted Date: 2017-09-20

Last Posted Date: 2023-04-05

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 30

Registration Number: NCT03289208

Locations: 🇯🇵
Investigational site, Tokyo, Japan

Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain

Phase 2

Completed

Conditions: Osteoarthritis, Knee / Osteoarthritis, Hip

Interventions: Drug: MT-5547
Drug: MT-5547-matching placebo

First Posted Date: 2017-08-10

Last Posted Date: 2023-05-17

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 626

Registration Number: NCT03245008

Locations: 🇯🇵
Investigational Site, Yamaguchi, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy